Polycystic Kidney Disease (PKD)
Polycystic Kidney Disease (PKD) in Secunderabad — Slow the Cysts, Protect the Family
At a glance
Condition
Polycystic Kidney Disease (PKD) — an inherited genetic disorder causing fluid-filled cysts to grow in the kidneys over decades
Two main types
ADPKD (Autosomal Dominant) — 1 in 1,000 people, presents in adulthood, 50% chance of inheriting. ARPKD (Autosomal Recessive) — rare, presents in infancy/childhood.
Most important fact
PKD has no cure — but cyst growth can be slowed with tolvaptan, and kidney failure can be delayed by years with specialist management.
Specialist PKD Management
★ Tolvaptan Therapy
The only disease-modifying therapy for rapidly progressing ADPKD. Slows cyst growth and kidney function decline. Available at KIMS — assessment required. Many ADPKD patients have never been offered this.
⚠ Brain aneurysm risk
ADPKD patients have a 5–8x higher risk of intracranial aneurysm. KIMS offers MRI brain screening for high-risk patients (family history of aneurysm or rupture).
Family screening
50% of first-degree relatives of an ADPKD patient have it. KIMS offers renal ultrasound family screening and genetic counselling.
When kidneys fail
PKD is one of the most common indications for kidney transplant. KIMS has performed 1,500+ transplants — including PKD patients.
Appointments
040 - 44885000 · assistance@kimshospitals.com — respond within 24 hours
What is polycystic kidney disease?
Polycystic kidney disease (PKD) is a genetic disorder in which hundreds to thousands of fluid-filled cysts grow progressively in the kidney tissue over decades. These cysts are not cancerous — but they displace normal kidney tissue, enlarge the kidneys dramatically (ADPKD kidneys can grow to 10–20 times their normal size), and progressively impair filtration function. PKD is the fourth most common cause of kidney failure worldwide, after diabetes, high blood pressure, and glomerulonephritis.
PKD comes in two very different forms — the genetics, timing, severity, and management of which differ fundamentally
ADPKD vs ARPKD — two completely different conditions
While both involve kidney cysts, the inheritance patterns, age of onset, and extra-renal complications differ fundamentally between these two forms of PKD.
| Feature | ADPKD — Autosomal Dominant PKD | ARPKD — Autosomal Recessive PKD |
|---|---|---|
| Inheritance | One copy of mutated gene causes disease. 50% of children of an affected parent will inherit ADPKD. | Both parents must carry one copy. 25% chance of affected child if both parents are carriers. |
| Prevalence | 1 in 1,000–2,500 people — most common inherited kidney disease. | ~1 in 20,000 — much rarer. |
| When it presents | Usually 30s–50s. Often silent for decades. | In utero, infancy, or early childhood. Much more severe. |
| Genes involved | PKD1 (chr. 16) — 78% · PKD2 (chr. 4) — 15%. PKD1 progresses faster. | PKHD1 gene. |
| Kidney Impact | Progressive cyst growth. Kidney failure in ~50% by age 60. | Cysts throughout both kidneys. Pulmonary hypoplasia in severe cases. |
| Extra-kidney | Liver cysts (80%) · Intracranial aneurysms (5–10%) · Heart valve abnormalities. | Liver fibrosis (portal hypertension). Often more severe than kidney disease. |
| Management | Tolvaptan · BP control · Cyst complications · Transplant. | Supportive · Liver transplant may be needed · Paediatric team essential. |
Symptoms — what PKD feels like
ADPKD is frequently silent for decades. Many patients first learn they have it when a family member is diagnosed and a screening ultrasound is done, or when a scan done for another reason reveals enlarged kidneys.
Flank or abdominal pain — from cyst growth stretching the kidney capsule, or from a cyst rupturing or bleeding (acute sudden pain)
Blood in the urine (haematuria) — from a cyst rupturing or bleeding into the urinary tract
High blood pressure — often the earliest abnormality, developing even before kidney function falls
Urinary tract infections — cysts can become infected, causing fever and back pain that does not fully respond to standard antibiotics
A palpable abdominal mass — enlarged kidneys become physically detectable in advanced disease
Increasing creatinine and falling eGFR — kidney function declining as cysts displace functional tissue
Severe, unrelenting fatigue — common as kidney function approaches failure
Early satiety — feeling full quickly as enlarged kidneys press on the stomach
⚠ EMERGENCY WARNING: Intracranial Aneurysm
Sudden severe head pain — 'the worst headache of my life' — in a PKD patient is an emergency. This pattern can indicate rupture of an intracranial aneurysm and requires immediate emergency assessment. Go to KIMS Emergency on 040 - 44885000 without delay. Do not take pain relief and wait. This is potentially fatal within hours.
How PKD is diagnosed at KIMS
In most adults, ADPKD is diagnosed by renal ultrasound — which shows enlarged kidneys with multiple bilateral cysts. Specific diagnostic criteria (the Ravine/Pei criteria) based on cyst number and age are used to confirm ADPKD in families with a known PKD1 or PKD2 mutation. For younger family members where ultrasound may not yet show sufficient cysts, a CT or MRI of the kidneys provides more sensitive detection.
Genetic testing for PKD1 and PKD2 mutations is available at KIMS — useful for individuals where imaging is equivocal, for family members who want definitive confirmation, and for individuals considering family planning. At KIMS, genetic counselling is offered alongside genetic testing to help patients and families understand the implications of results.
Total Kidney Volume (TKV) measurement by MRI is performed at KIMS for patients being considered for tolvaptan therapy — it is the most precise measure of cyst burden and the primary criterion for determining who has 'rapidly progressing' disease qualifying for tolvaptan.
PKD management at KIMS — slowing progression and preventing complications
Managing PKD at KIMS Secunderabad is a proactive, long-term programme. We focus on the only disease-modifying therapy (Tolvaptan), intensive blood pressure targets, and the early detection of life-threatening extra-renal complications like brain aneurysms.
| Focus Area | What is happening | KIMS Approach |
|---|---|---|
| Tolvaptan Therapy | The only proven medication (Jinarc/Samsca) to slow cyst growth and kidney function decline by 30–40% in rapidly progressing cases. | Formal assessment of eGFR and Total Kidney Volume (MRI). Initiation and monthly liver function monitoring for eligible ADPKD patients. |
| BP Control | High blood pressure accelerates cyst expansion. Targets: <110/75 for age <50; <130/80 for older or advanced cases. | First-line use of ACE inhibitors or ARBs to reduce intraglomerular pressure and provide additional kidney protection. |
| Aneurysm Screening | ADPKD patients have a 5–8x higher risk of intracranial aneurysms, which are often silent until rupture. | MRI Brain Angiogram for high-risk patients (family history of rupture or high-risk professions) in coordination with KIMS Neurology. |
| Cyst Complications | Cyst haemorrhage causes acute pain/blood in urine. Infections require antibiotics that can penetrate cyst fluid. | Hydration and analgesia for bleeds. Fluoroquinolone therapy for 6–8 weeks for infections. Cyst decortication for intractable pain. |
| Kidney Stones | Occur in 20% of PKD patients due to low urine pH and urinary stasis from cyst compression. | Advanced laser stone management (RIRS or Mini-PCNL) through the dedicated KIMS Laser Stone Centre. |
| Family Screening | First-degree relatives have a 50% chance of inheritance. Early detection allows for better long-term protection. | Structured renal ultrasound screening for adults 18+. Genetic counseling for family planning and definitive mutation testing. |
| Kidney Failure | Native PKD kidneys can grow 10–20x normal size. Transplant provides a normal, cyst-free kidney. | Transplant evaluation starting at Stage 4 CKD. Over 1,500 transplants performed with excellent outcomes for PKD recipients. |
Why choose KIMS Secunderabad for PKD?
Tolvaptan assessment and initiation
Offered to every eligible patient. The majority of ADPKD patients in Hyderabad have never been assessed for tolvaptan because they are not seeing a nephrologist who specialises in PKD management. At KIMS, every ADPKD patient is formally assessed using MRI-based total kidney volume measurement and eGFR trajectory to determine whether they qualify for tolvaptan. Those who qualify are offered it with monitoring.
Intracranial aneurysm screening pathway
Neurology on the same campus. KIMS provides MRI brain angiogram for high-risk ADPKD patients, with immediate access to the neurology and neurosurgery team within the same 1,000-bed campus for identified aneurysms. A PKD patient who is found to have an unruptured aneurysm on screening does not need to be referred elsewhere for further assessment or management.
1,500+ kidney transplants
Including PKD patients. When PKD kidneys eventually fail, KIMS's transplant programme — one of South India's most experienced, with live donor, cadaveric, and ABO-incompatible options — is the seamless next step. The same nephrology team that managed the PKD for years coordinates the transplant evaluation and post-transplant care.
Family screening & genetic counselling
The PKD diagnosis does not end with the patient — it extends to their family. KIMS provides a structured family screening programme and genetic counselling to help relatives understand their risk, decide whether to be tested, and plan accordingly.
Specialized Radiology Support
Precise monitoring of PKD requires expert imaging. Our radiology team is trained in specific Total Kidney Volume (TKV) measurement protocols, which are essential for tracking disease progression and determining eligibility for advanced pharmaceutical interventions.
Comprehensive Complication Management
From infected cysts requiring specific antibiotic penetration to managing PKD-related kidney stones via our dedicated Laser Stone Centre, KIMS offers the multi-disciplinary infrastructure required to handle the complex secondary effects of polycystic disease.
Book a PKD Specialist Consultation at KIMS
Our PKD specialists at KIMS Secunderabad
Our nephrology team provides specialized management for Polycystic Kidney Disease, ensuring that patients receive access to the latest disease-modifying therapies and coordinated transplant care when needed.
Frequently Asked Questions
If you have ADPKD (autosomal dominant PKD — the most common type), each of your biological children has a 50% chance of inheriting it. This is not a certainty — but it is a significant risk. Family screening with a kidney ultrasound is the most straightforward way to assess whether an adult family member has inherited ADPKD. KIMS offers a family screening programme — renal ultrasound for first-degree relatives over the age of 18, with genetic counselling to help the family understand the implications. Screening children under 18 is generally not recommended unless there are clinical reasons, since a positive result in childhood currently changes very little about management and may cause significant anxiety.
Tolvaptan (Jinarc/Samsca) is a vasopressin receptor antagonist — the only medication proven in large clinical trials (TEMPO 3:4 and REPRISE) to slow cyst growth and kidney function decline in rapidly progressing ADPKD. It reduces kidney volume growth and slows the annual eGFR fall by approximately 30–40% in eligible patients. It is taken daily as a tablet and requires regular liver function monitoring (monthly initially). Tolvaptan is not suitable for all ADPKD patients — it is indicated for adults with rapidly progressing disease (defined by age, eGFR level, and total kidney volume measured by MRI). At KIMS, every ADPKD patient is formally assessed to determine whether they qualify. Many patients who come to KIMS from other clinics have never been offered this assessment.
ADPKD patients have a 5–8 times higher risk of intracranial aneurysm than the general population. Not all ADPKD patients require routine brain scanning — but high-risk patients should be screened. KIMS recommends MRI brain angiogram (no radiation, non-invasive) for ADPKD patients with: a first-degree family member who has had a brain aneurysm or subarachnoid haemorrhage; a high-risk occupation (pilot, surgeon, commercial driver); or new or unusual headaches. Seek emergency assessment immediately if you experience a sudden, severe headache — 'the worst headache of your life' — this can indicate aneurysm rupture and requires emergency treatment within hours. Call 040 - 44885000.
There is currently no cure for PKD — the underlying genetic mutation cannot be corrected with currently available treatments. However, 'no cure' does not mean 'nothing can be done'. Tolvaptan meaningfully slows cyst growth and kidney function decline in rapidly progressing ADPKD. Intensive blood pressure control (below 110/75 mmHg in younger patients) slows cyst volume growth. Adequate hydration, avoiding caffeine and tobacco, and kidney stone prevention all contribute to protecting kidney function. Many ADPKD patients maintain functional kidney health into their 60s and 70s with good specialist management. And when kidneys eventually fail, transplantation at KIMS provides a functioning kidney — and the transplanted kidney does not develop PKD cysts.
Progression varies significantly — patients with PKD1 mutations (the more common type, accounting for 78% of ADPKD cases) progress faster than those with PKD2 mutations. On average, approximately 50% of ADPKD patients develop kidney failure by age 60, and 60% by age 70 — though with good specialist management, these timelines can be extended. KIMS tracks kidney function trajectory (rate of eGFR decline per year), total kidney volume by MRI, and blood pressure control to predict and plan for kidney failure — beginning transplant preparation at Stage 4 CKD (eGFR 15–29), well before kidney failure arrives.
Yes — and exercise is actively encouraged for PKD patients. Regular aerobic exercise (walking, swimming, cycling — 30 minutes most days) helps control blood pressure, reduces cardiovascular risk, maintains a healthy weight (obesity accelerates PKD progression), and is associated with better quality of life. Contact sports that risk direct abdominal trauma (martial arts, rugby, contact football) should be avoided, as the enlarged kidneys in advanced PKD are vulnerable to injury. There are no significant dietary restrictions specific to PKD beyond the general kidney-protective advice that applies at each CKD stage (sodium restriction, adequate hydration — target 2.5 to 3 litres of water per day). Caffeine should be limited — it may stimulate cyst growth through its effect on the same signalling pathway that tolvaptan blocks.
The most evidence-supported lifestyle interventions for ADPKD are: high water intake (2.5–3 litres per day — suppresses vasopressin, the hormone that drives cyst growth — mimicking part of how tolvaptan works); aggressive blood pressure control; avoiding smoking and excessive alcohol; maintaining a healthy weight; limiting caffeine; and a balanced moderate-protein diet with low sodium. The KIMS nephrology team provides personalised lifestyle guidance at each PKD clinic visit — not generic advice.
KIMS Secunderabad offers the most comprehensive PKD programme in the region: formal tolvaptan assessment by MRI-based total kidney volume measurement for every eligible patient; intracranial aneurysm screening pathway with neurology within the same campus; family screening and genetic counselling; over 1,500 kidney transplants for when PKD kidneys eventually fail; paediatric renal team for ARPKD; and continuous, long-term nephrology management by DM-qualified specialists. KIMS is Times Healthcare Achievers — Best Hospital of the Year in Nephrology, NABH and NABL accredited, and empanelled under Aarogyasri, CGHS, and EHS.